Targeting Metastasis at the Root: Precision Therapy and Companion Diagnostics - EIC Pathfinder Planning

Purpose and goal

MetaCurUm Biotech is developing Meta-CD, a novel cancer treatment that targets a new oncogenic pathway to stop cancer progression and metastasis. The company plans to apply to the EIC Pathfinder call in 2026 to secure funding to demonstrate proof of concept for Meta-CD and prepare for first human trials. In this project, our goal is to build an eligible consortium and refine the scientific and technological work plan to strengthen the EIC Pathfinder application.

Expected effects and result

The project will prepare MetaCurUm for applying to the EIC Pathfinder call. Expected results include a final consortium, a detailed project work plan with a timeline and budget, and a set of strategic documents. These will support the scientific, regulatory, and financial positioning of the new therapy. The project will also deliver a report on expected social and economic impact and an initial communication strategy. All results will support a strong EIC Pathfinder application.

Planned approach and implementation

The project will run from December 2025 to May 2026. The work will be organised into five complementary work packages that cover the key elements of a strong funding application. WP1 will define the project work plan and budget. WP2 will focus on building the consortium. WP3 will define the positioning of the new therapy. WP4 will address social and economic impact and the communication strategy. WP5 will combine all results into a competitive EIC Pathfinder application.